A series of studies such as CheckMate153 and IMPOWER130 have shown that NSCLC patients with EGFR or ALK mutations hardly benefit from immunotherapy alone [20, 24, 25, 26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.